Positive Results from Phase 2B Study into Patients with Gout
Published: Monday, January 16, 2012 Last Updated: Monday, January 16, 2012
BioCryst Pharmaceuticals, Inc. announce results from its randomized Phase 2b study of BCX4208 added to allopurinol in patients with gout who had failed to reach the serum uric acid therapeutic goal of <6 mg/dL on allopurinol alone.
Full access to this article is for registered users only. Registration is free-of-charge and allows access to all content on our web communities.
Already registered? Then please log in at the top of the page.